The Constitutive Activation of Jak2-V617F Is Mediated by a π Stacking Mechanism Involving Phenylalanines 595 and 617

被引:31
作者
Gnanasambandan, Kavitha [1 ]
Magis, Andrew [2 ]
Sayeski, Peter P. [1 ]
机构
[1] Univ Florida, Coll Med, Dept Physiol & Funct Genom, Gainesville, FL 32610 USA
[2] Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA
基金
美国国家卫生研究院;
关键词
JAK2 TYROSINE KINASE; POLYCYTHEMIA-VERA; MYELOPROLIFERATIVE DISORDERS; PSEUDOKINASE DOMAIN; MOLECULAR-DYNAMICS; V617F MUTATION; INHIBITOR; NEOPLASMS; PROTEINS; RECEPTOR;
D O I
10.1021/bi1014858
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Somatic mutations in the Jak2 allele that lead to constitutive kinase activation of the protein have been identified in human disease conditions such as the myeloproliferative neoplasms (MPNs). The most common mutation in these patients is a V617F substitution mutation, which is believed to play a causative role in the MPN pathogenesis. As such, identifying the molecular basis for the constitutive activation of Jak2-V617F is important for understanding its clinical implications and potential treatment. Here, we hypothesized that conversion of residue 617 from Val to Phe resulted in the formation of novel pi stacking interactions with neighboring Phe residues. To test this, we first examined the Jak2 structure via molecular modeling and identified a potential pi stacking interaction between F594, F595, and F617. Disruption of this interaction through site-directed mutagenesis impaired Jak2 autophosphorylation, Jak2-dependent gene transcription, and in vitro kinase activity of the Jak2-V617F protein. Further, substitution of F594 and F595 with Trp did not affect Jak2 function significantly, but replacement with charged residues did, showing the importance of aromaticity and hydropathy index conservation at these positions. Using molecular dynamics (MD) simulations, we found that the pi stacking interaction between residues 595 and 617 in the Jak2-V617F protein was of much greater energy and conformed to the properties of pi stacking, relative to the Jak2-WT or Jak2-V617F/F594A/F595A. In summary, we have identified a pi stacking interaction between F595 and F617 that is specific to and is critical for the constitutive activation of Jak2-V617F.
引用
收藏
页码:9972 / 9984
页数:13
相关论文
共 44 条
  • [21] Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
    Levine, Ross L.
    Pardanani, Animesh
    Tefferi, Ayalew
    Gilliland, D. Gary
    [J]. NATURE REVIEWS CANCER, 2007, 7 (09) : 673 - 683
  • [22] Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation
    Lindauer, K
    Loerting, T
    Liedl, KR
    Kroemer, RT
    [J]. PROTEIN ENGINEERING, 2001, 14 (01): : 27 - 37
  • [23] The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor
    Lucet, IS
    Fantino, E
    Styles, M
    Bamert, R
    Patel, O
    Broughton, SE
    Walter, M
    Burns, CJ
    Treutlein, H
    Wilks, AF
    Rossjohn, J
    [J]. BLOOD, 2006, 107 (01) : 176 - 183
  • [24] π-stacking interactions -: Alive and well in proteins
    McGaughey, GB
    Gagné, M
    Rappé, AK
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (25) : 15458 - 15463
  • [25] Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis
    Neubauer, H
    Cumano, A
    Muller, M
    Wu, H
    Huffstadt, U
    Pfeffer, K
    [J]. CELL, 1998, 93 (03) : 397 - 409
  • [26] TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations
    Pardanani, A.
    Hood, J.
    Lasho, T.
    Levine, R. L.
    Martin, M. B.
    Noronha, G.
    Finke, C.
    Mak, C. C.
    Mesa, R.
    Zhu, H.
    Soll, R.
    Gilliland, D. G.
    Tefferi, A.
    [J]. LEUKEMIA, 2007, 21 (08) : 1658 - 1668
  • [27] Jak2 is essential for signaling through a variety of cytokine receptors
    Parganas, E
    Wang, D
    Stravopodis, D
    Topham, DJ
    Marine, JC
    Teglund, S
    Vanin, EF
    Bodner, S
    Colamonici, OR
    van Deursen, JM
    Grosveld, G
    Ihle, JN
    [J]. CELL, 1998, 93 (03) : 385 - 395
  • [28] UCSF chimera - A visualization system for exploratory research and analysis
    Pettersen, EF
    Goddard, TD
    Huang, CC
    Couch, GS
    Greenblatt, DM
    Meng, EC
    Ferrin, TE
    [J]. JOURNAL OF COMPUTATIONAL CHEMISTRY, 2004, 25 (13) : 1605 - 1612
  • [29] Scalable molecular dynamics with NAMD
    Phillips, JC
    Braun, R
    Wang, W
    Gumbart, J
    Tajkhorshid, E
    Villa, E
    Chipot, C
    Skeel, RD
    Kalé, L
    Schulten, K
    [J]. JOURNAL OF COMPUTATIONAL CHEMISTRY, 2005, 26 (16) : 1781 - 1802
  • [30] Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
    Quintas-Cardama, Alfonso
    Vaddi, Kris
    Liu, Phillip
    Manshouri, Taghi
    Li, Jun
    Scherle, Peggy A.
    Caulder, Eian
    Wen, Xiaoming
    Li, Yanlong
    Waeltz, Paul
    Rupar, Mark
    Burn, Timothy
    Lo, Yvonne
    Kelley, Jennifer
    Covington, Maryanne
    Shepard, Stacey
    Rodgers, James D.
    Haley, Patrick
    Kantarjian, Hagop
    Fridman, Jordan S.
    Verstovsek, Srdan
    [J]. BLOOD, 2010, 115 (15) : 3109 - 3117